Document is current
Any future updates will be listed below
-
Authors
Pattni, Karan
Hungerford, Daniel
Adams, Sarah
Buchan, Iain
Cheyne, Christopher P.
García-Fiñana, Marta
Hall, Ian
Hughes, David M.
Overton, Christopher E.
Zhang, Xingna
Sharkey, Kieran J. https://orcid.org/0000-0002-7210-9246
-
Funding
Funding for this research was provided by:
Engineering and Physical Sciences Research Council (EP/T031727/1, EP/T031727/1)
National Institute for Health Research (PDF-2018-11-ST2-006)
National Institute for Health Research (NIHR200910)
- License Information
-
More Information
Article History
Received: 21 October 2021
Accepted: 3 March 2022
First Online: 20 March 2022
Declarations
:
: The University of Liverpool provided secondary data analysis on fully anonymised data. As per the National Health Service (NHS) Health Research Authority guidelines, this work did not require ethical approval. Cheshire & Merseyside Health & Care Partnership Combined Intelligence for Population Health Action (CIPHA) Data Asset and Access Group approved access to the anonomysed data contained in the study. MAST (mass, asymptomatic, serial testing)/SMART (systematic, meaningful, asymptomatic/agile, repeated testing) was defined as ‘an emergency public health intervention during an extraordinary event’ which were subject to the legal and ethical provisions of a health protection activity and COVID-19 specifically. The secondary analysis of data provided in a health protection activity is not classified as research, and so does not require research ethics committee review (see ).
: Not applicable.
: IB is Chief Data Scientist Advisor for AstraZeneca.
